This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brown, J. M. Articles by Lemmon, M. J. Search for Related Content PubMed PubMed Citation Articles by Brown, J. M. Articles by Lemmon, M. J.

Potentiation by the Hypoxic Cytotoxin SR 4233 of Cell Killing Produced by Fractionated Irradiation of Mouse Tumors¹

Division of Radiation Biology, Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California 94305

The new bioreductive drug 3-amino-1,2,4-benzotriazine 1,4-dioxide (SR 4233) shows a high selective cytotoxicity for hypoxic cells, both in vitro and in tumors in vivo. In the present experiments, we have tested the hypothesis that this selective killing of hypoxic cells might be exploited by taking advantage of the fluctuating hypoxia in tumors by use of a multidose regimen of SR 4233 with multiple small doses of X-rays. We have tested four different transplantable mouse tumors using a standard fractionated protocol of 8 x 2.5 Gy in 4 days, using a well tolerated dose of SR 4233 given with each radiation dose. All of the tumors showed a substantial enhancement of cell killing by SR 4233 over that produced by radiation alone with dose-modifying factors of 1.5 to 3.0 for the different tumors. In all four tumors, the enhancement of cell killing was greater than that produced by a large dose of the hypoxic cell sensitizer SR 2508 given before each irradiation, thereby demonstrating the superiority of the approach of using a hypoxic cytotoxic agent rather than a radiosensitizer in fractionated radiation protocols. The data suggest that SR 4233 has considerable promise as an adjunct to standard radiotherapy.

¹ This investigation was supported by Grant CA 15201 from the National Cancer Institute, Department of Health and Human Services.

² To whom requests for reprints should be addressed.

Received 7/16/90. Accepted 9/17/90.

This article has been cited by other articles:

				R L Cowen, E J Garside, B Fitzpatrick, M V Papadopoulou, and K J Williams Gene therapy approaches to enhance bioreductive drug treatment Br. J. Radiol., October 1, 2008; 81(Special_Issue_1): S45 - S56. [Abstract] [Full Text] [PDF]

				O. Riesterer, L. Milas, and K. K. Ang Use of Molecular Biomarkers for Predicting the Response to Radiotherapy With or Without Chemotherapy J. Clin. Oncol., September 10, 2007; 25(26): 4075 - 4083. [Abstract] [Full Text] [PDF]

				R. Beck, B. Roper, J. M. Carlsen, M. C. Huisman, J. A. Lebschi, N. Andratschke, M. Picchio, M. Souvatzoglou, H.-J. Machulla, and M. Piert Pretreatment 18F-FAZA PET Predicts Success of Hypoxia-Directed Radiochemotherapy Using Tirapazamine J. Nucl. Med., June 1, 2007; 48(6): 973 - 980. [Abstract] [Full Text] [PDF]

				D. Rischin, R. J. Hicks, R. Fisher, D. Binns, J. Corry, S. Porceddu, and L. J. Peters Prognostic Significance of [18F]-Misonidazole Positron Emission Tomography-Detected Tumor Hypoxia in Patients With Advanced Head and Neck Cancer Randomly Assigned to Chemoradiation With or Without Tirapazamine: A Substudy of Trans-Tasman Radiation Oncology Group Study 98.02 J. Clin. Oncol., May 1, 2006; 24(13): 2098 - 2104. [Abstract] [Full Text] [PDF]

				E. E.W. Cohen, M. W. Lingen, and E. E. Vokes The Expanding Role of Systemic Therapy in Head and Neck Cancer J. Clin. Oncol., May 1, 2004; 22(9): 1743 - 1752. [Abstract] [Full Text] [PDF]

				R. L. Cowen, K. J. Williams, E. C. Chinje, M. Jaffar, F. C. D. Sheppard, B. A. Telfer, N. S. Wind, and I. J. Stratford Hypoxia Targeted Gene Therapy to Increase the Efficacy of Tirapazamine as an Adjuvant to Radiotherapy: Reversing Tumor Radioresistance and Effecting Cure Cancer Res., February 15, 2004; 64(4): 1396 - 1402. [Abstract] [Full Text] [PDF]

				N Raghunand, R A Gatenby, and R J Gillies Microenvironmental and cellular consequences of altered blood flow in tumours Br. J. Radiol., December 1, 2003; 76(suppl_1): S11 - S22. [Abstract] [Full Text] [PDF]

				M. V. Papadopoulou and W. D. Bloomer NLCQ-1 (NSC 709257): Exploiting Hypoxia with a Weak DNA-Intercalating Bioreductive Drug Clin. Cancer Res., November 15, 2003; 9(15): 5714 - 5720. [Abstract] [Full Text] [PDF]

				G. Lammering, T. H. Hewit, W. T. Hawkins, J. N. Contessa, D. B. Reardon, P.-S. Lin, K. Valerie, P. Dent, R. B. Mikkelsen, and R. K. Schmidt-Ullrich Epidermal Growth Factor Receptor as a Genetic Therapy Target for Carcinoma Cell Radiosensitization J Natl Cancer Inst, June 20, 2001; 93(12): 921 - 929. [Abstract] [Full Text] [PDF]

				D. Rischin, L. Peters, R. Hicks, P. Hughes, R. Fisher, R. Hart, M. Sexton, I. D'Costa, and R. von Roemeling Phase I Trial of Concurrent Tirapazamine, Cisplatin, and Radiotherapy in Patients With Advanced Head and Neck Cancer J. Clin. Oncol., January 15, 2001; 19(2): 535 - 542. [Abstract] [Full Text] [PDF]

				J. M. Brown The Hypoxic Cell: A Target for Selective Cancer Therapy--Eighteenth Bruce F. Cain Memorial Award Lecture Cancer Res., December 1, 1999; 59(23): 5863 - 5870. [Abstract] [Full Text] [PDF]